Research programme: oncobiotic therapeutics - Evelo Biosciences

Drug Profile

Research programme: oncobiotic therapeutics - Evelo Biosciences

Alternative Names: Immuno-microbiome Cancer therapies - Evelo Biosciences; Microbiome-based immuno-oncology therapeutics - Evelo Biosciences; Onco-microbials - Evelo Biosciences

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator University of Chicago
  • Developer Evelo Biosciences
  • Class Antineoplastics; Bacteria; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Aug 2016 Evelo Biosciences and Mayo Clinic enter into an exclusive collaboration agreement for the development of oncobiotic therapies
  • 13 Apr 2016 Oncobiotic therapeutics licensed to Evolo Biosciences worldwide .
  • 12 Apr 2016 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top